Roche’s phase III persevERA Breast Cancer study of giredestrant in combo with palbociclib ER-positive advanced breast cancer fails to meet its primary objective: Basel Tuesday, ...

Dr Mark Kris highlights a recent study on osimertinib in NSCLC and outlines the best approaches for treatment beyond progression.

华东医药表示，本次注射用HDM2024美国临床试验获批，是该款产品研发进程中的又一重要进展，将进一步提升公司在肿瘤治疗领域的核心竞争力。根据美国药品注册相关的法律法规要求，药物在获得临床试验批准通知书后，尚需开展一系列临床试验并经美国FDA批准后方可上市。此次获得临床试验批准，对公司近期业绩不会产生重大影响。药品研发存在投入大、周期长、风险高等特点，临床试验进度及结果、未来产品市场竞争形势均存在诸 ...

Silevertinib, a fourth‑generation EGFR inhibitor targeting non‑classical EGFR mutations and GBM, has a near‑term catalyst: the company plans to present frontline NSCLC PFS data next quarter, and Black ...

persevERA is the first of two distinct Phase III studies in the first-line setting; the pionERA study of giredestrant in ...

Data show T-DXd improves invasive disease-free survival and reduces the risk of distant recurrence in early HER2-positive breast cancer.

Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected mid-2026Global pivotal Phase 3 ...

Roche Holdings AG RHHBY on Monday shared results from the phase 3 persevERA Breast Cancer study of giredestrant combined with palbociclib in advanced cancer patients. Trial Misses Primary Goal The ...

The study did not meet its primary objective of a statistically significant improvement in progression-free survival in the intent-to-treat population versus letrozole plus palbociclib, but a ...

NEWTOWN SQUARE, PA — ArriVent BioPharma Inc. (Nasdaq: AVBP) reported financial results for the year ended December 31, 2025, and said it expects pivotal Phase 3 data for its lung ...

Roche RHHBY announced results from a late-stage study evaluating its investigational candidate, giredestrant, in combination with palbociclib for patients with estrogen receptor (ER)-positive, human ...

As previously presented, gedatolisib + palbociclib + fulvestrant (“gedatolisib triplet”) and gedatolisib + fulvestrant (“gedatolisib doublet”) ...